Sirolimus- vs. paclitaxel-eluting stents in patients undergoing off-label percutaneous coronary intervention

Studies of percutaneous coronary intervention (PCI) with drug-eluting stents in high-risk scenarios are often limited by short follow up and use definitions of "off-label" PCI which do not entirely mirror insert packages recommendations. We analyzed the incidence of cardiovascular events in 1050 consecutive patients undergoing off-label PCI with sirolimus- (n=581) or paclitaxel- (n=469) eluting stents. At 3 years, there were no differences between groups in terms of major cardiovascular events (adjusted hazard ratio 0.991; 95% CI, 0.758 to 1.295; p=0.945), despite slightly higher rates of myocardial infarction and late stent thrombosis seen among patients who received paclitaxel-eluting stents.